Home> Products> potent antidiabetic agents

{ "products": [ { "_id": "6825c6cc966e2a18bb4b35a6", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA PIO", "description": "GLIDAPA PIO is a combination oral medication specially formulated to help manage type 2 diabetes mellitus. It combines two powerful antidiabetic agents, dapagliflozin and pioglitazone, to effectively control blood sugar levels. This medication is prescribed to patients when diet and exercise alone do not provide adequate glycemic control. By addressing blood glucose regulation through different mechanisms, GLIDAPA PIO helps reduce the risk of diabetes-related complications and supports overall metabolic health.\n\nKey Ingredients\nDapagliflozin (10mg): A sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by increasing the excretion of glucose through urine.\n\nPioglitazone (15mg): A thiazolidinedione that improves insulin sensitivity by acting on fat, muscle, and liver cells, facilitating better glucose uptake and utilization.\n\nKey Benefits\nHelps maintain stable blood glucose levels in adults with type 2 diabetes.\n\nCombines two complementary mechanisms to enhance blood sugar control.\n\nSupports weight management due to dapagliflozin’s glucose excretion effect.\n\nMay improve insulin sensitivity and reduce insulin resistance.\n\nReduces the risk of diabetes-related complications such as cardiovascular problems when combined with lifestyle changes.\n\nConvenient once-daily tablet formulation.\n\nHow Does It Work?\nDapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting its elimination through urine, which lowers blood glucose. Pioglitazone acts on insulin-responsive tissues, enhancing the body’s sensitivity to insulin. This dual action helps reduce both insulin resistance and excess blood glucose, providing better overall glycemic control. By targeting different pathways, GLIDAPA PIO offers a synergistic effect to manage type 2 diabetes more effectively.\n\nDirections for Use\nTake GLIDAPA PIO exactly as prescribed by your healthcare provider.\n\nUsually taken once daily, with or without food, at the same time each day.\n\nDo not skip doses or stop the medication without consulting your doctor.\n\nMaintain a balanced diet and regular exercise as advised alongside the medication.\n\nInform your doctor about any other medications you are taking to avoid potential interactions.\n\nSide Effects\nSome patients may experience side effects while taking GLIDAPA PIO, including:\n\nUrinary tract infections or increased urination due to dapagliflozin.\n\nWeight gain or swelling caused by pioglitazone.\n\nRisk of low blood sugar (hypoglycemia) when combined with other antidiabetic drugs.\n\nPossible dizziness or fatigue.\n\nRarely, heart failure or bladder cancer risk (associated with pioglitazone).\n\nIf you notice symptoms like excessive thirst, sudden weight gain, swelling, shortness of breath, or any allergic reactions, seek medical advice immediately.", "price": 255.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medication inform", "pioglitazone risk", "regular exercise", "balanced diet", "doctor maintain", "glucose uptake", "notice symptoms", "antidiabetic drugs", "swelling caused", "advised alongside", "skip doses", "healthcare provider", "effectively directions", "synergistic effect", "glycemic control", "cardiovascular problems", "complementary mechanisms", "fat muscle", "diabetesrelated complications", "insulin resistance", "bodys sensitivity", "glidapa pio", "urine pioglitazone 15mg", "taking glidapa pio", "bladder cancer risk", "improve insulin sensitivity", "improves insulin sensitivity", "glidapa pioglidapa pio", "dapagliflozin weight gain", "increased urination due", "urinary tract infections", "experience side effects", "insulinresponsive tissues enhancing", "liver cells facilitating" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2114, "imageuri": "https://productimages.withfloats.com/actual/6825c6ce65488af627fb2e46.png", "tileimageuri": "https://productimages.withfloats.com/tile/6825c6ce65488af627fb2e46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-15T10:49:48.361Z", "updatedon": "2025-05-15T10:50:30.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-pio/2114", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Dapagliflozin 10mg and pioglitazone 15mg tablets", "category": "DIABETIC RANGE", "tags": [ "Dapagliflozin, pioglitazone combination", "Dapagliflozin, pioglitazone combination", "Dapagliflozin Pioglitazone CDSCO" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668d24ff75f1701d34699e32", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE 80 ", "description": "GLICLAGLAZE 80 \nGliclazide (80mg)\nOverview\nGLICLAGLAZE 80 is an oral medication containing Gliclazide at a dosage of 80 mg. Gliclazide belongs to the class of drugs known as sulfonylureas and is primarily used to manage type 2 diabetes mellitus. It helps control blood sugar levels by stimulating the release of insulin from the pancreatic beta cells. GLICLAGLAZE 80 is an effective treatment option for individuals who require oral hypoglycemic therapy to maintain optimal blood glucose levels.\n\nBenefits of Gliclazide\n\nBlood Sugar Control\n\nGliclazide effectively lowers blood glucose levels by increasing insulin secretion.\nHelps prevent complications associated with diabetes, such as neuropathy, nephropathy, and retinopathy.\nReduced Risk of Hypoglycemia\n\nCompared to some other sulfonylureas, Gliclazide has a lower risk of causing hypoglycemia (low blood sugar levels).\nIt provides a balanced approach to managing blood sugar without causing excessive drops in glucose levels.\nCardiovascular Benefits\n\nStudies suggest that Gliclazide may have a protective effect on the cardiovascular system.\nIt may reduce the risk of cardiovascular events in diabetic patients, promoting overall heart health.\nImproved Glycemic Control\n\nHelps achieve and maintain target HbA1c levels, reflecting long-term glycemic control.\nCan be used in combination with other oral antidiabetic agents or insulin to enhance its effectiveness.\nUsage and Dosage\nGLICLAGLAZE 80 should be taken as prescribed by a healthcare professional. The typical starting dose is 40 to 80 mg daily, which can be adjusted based on the patient's blood glucose response. It is usually taken with meals to maximize its effectiveness and minimize gastrointestinal side effects. Consistent use and adherence to prescribed dosage are crucial for optimal results.\n\nIndications for Use\n\nType 2 Diabetes Mellitus: GLICLAGLAZE 80 is indicated for the management of type 2 diabetes in patients who cannot achieve adequate glycemic control through diet and exercise alone.\nCombination Therapy: It can be used in conjunction with other oral hypoglycemic agents or insulin to achieve better blood sugar control.\nSide Effects\nGLICLAGLAZE 80 is generally well-tolerated. However, some patients may experience side effects, including:\n\nHypoglycemia: Although less common, low blood sugar can occur, especially if meals are skipped or combined with excessive physical activity.\nGastrointestinal Issues: Nausea, abdominal pain, and diarrhea may occur but are usually mild and transient.\nAllergic Reactions: Rarely, allergic reactions such as skin rash, itching, or hives may occur.\nPrecautions and Contraindications\n\nLiver and Kidney Impairment: Patients with severe liver or kidney disease should use GLICLAGLAZE 80 with caution, as it may require dose adjustments.\nPregnancy and Lactation: Gliclazide is not recommended during pregnancy or breastfeeding. Alternative treatments should be considered.\nDrug Interactions: Inform your healthcare provider about all medications and supplements you are taking, as Gliclazide can interact with other drugs, potentially altering its effectiveness.\nConclusion\nGLICLAGLAZE 80 is a reliable and effective oral medication for managing type 2 diabetes mellitus. By stimulating insulin secretion, it helps control blood sugar levels, reducing the risk of diabetes-related complications. Its balanced approach to glycemic control, combined with potential cardiovascular benefits, makes GLICLAGLAZE 80 a valuable addition to diabetes management plans. Under the guidance of a healthcare professional, GLICLAGLAZE 80 can significantly improve the quality of life for individuals with type 2 diabetes, promoting better long-term health outcomes.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 265.0, "discountamount": 79.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "skin rash", "lower risk", "40 to 80 mg", "other drugs", "severe liver", "Reduced Risk", "Consistent use", "kidney disease", "abdominal pain", "excessive drops", "optimal results", "dose adjustments", "diabetic patients", "insulin secretion", "valuable addition", "Drug Interactions", "Kidney Impairment", "protective effect", "balanced approach", "Allergic Reactions", "healthcare provider", "Combination Therapy", "other sulfonylureas", "Blood Sugar Control", "target HbA1c levels", "overall heart health", "cardiovascular events", "cardiovascular system", "typical starting dose", "pancreatic beta cells", "Alternative treatments", "blood glucose response", "low blood sugar levels", "healthcare professional", "Gastrointestinal Issues", "type 2 diabetes mellitus", "diabetes management plans", "adequate glycemic control", "effective oral medication", "long-term health outcomes", "oral hypoglycemic therapy", "long-term glycemic control", "effective treatment option", "excessive physical activity", "optimal blood glucose levels", "gastrointestinal side effects", "diabetes-related complications", "other oral hypoglycemic agents", "other oral antidiabetic agents", "potential cardiovascular benefits" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1922, "imageuri": "https://productimages.withfloats.com/actual/668d2505c34ba6457aa3fb4d.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668d2505c34ba6457aa3fb4d.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-09T11:54:39.186Z", "updatedon": "2024-07-09T11:54:39.186Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-80-/1922", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE 80 ", "category": "DIABETIC RANGE", "tags": [ "Gliclazide 80mg side effects", "Gliclazide 80mg dosage", "Gliclazide 80mg Metformin 500mg", "Gliclazide 80mg price", "Gliclazide 80mg uses", "Gliclazide 80mg Uses in Hindi", "Gliclazide 80mg before or after meal" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef5bda743fd235821deeb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE M 80 ", "description": "GLICLAGLAZE M 80 \ngliclazide (80mg),Metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 80 is a specialized medication formulated for individuals diagnosed with Type 2 diabetes, aiming to enhance blood sugar regulation. This oral medication combines Gliclazide (80 mg) with Metformin (500 mg), two effective antidiabetic agents that provide a synergistic effect to control high blood sugar.\n\nMechanism of Action\n\nGliclazide (80 mg): Belonging to the sulfonylurea class, Gliclazide works by increasing insulin secretion from the pancreatic beta cells. It promotes a decrease in blood glucose levels and enhances the action of insulin in the body. Additionally, Gliclazide improves blood flow and has protective effects against the vascular complications of diabetes.\nMetformin (500 mg): Metformin reduces hepatic glucose production and improves insulin sensitivity by enhancing peripheral glucose uptake, particularly in muscle cells. This action helps lower blood glucose levels without the risk of inducing hypoglycemia and is associated with a potential reduction in body weight.\nBenefits\nGLICLAGLAZE M 80 offers a robust approach to managing Type 2 diabetes by targeting different aspects of the disease. The combination of Gliclazide and Metformin in this medication helps to control blood sugar more effectively than either component alone, potentially lowering the patient's risk of diabetes-related complications.\n\nDosage and Administration\n\nDosage: The starting dose should be adjusted based on the patient’s previous medication regimen, effectiveness, and tolerability. Dose adjustments should be made based on glycemic control, as assessed by regular monitoring of blood glucose levels.\nAdministration: It is recommended to take GLICLAGLAZE M 80 with meals to maximize drug absorption and minimize potential gastrointestinal side effects.\nSide Effects\nPotential side effects of GLICLAGLAZE M 80 include gastrointestinal symptoms like nausea and diarrhea, which usually improve over time. The risk of hypoglycemia exists but is moderated by the inclusion of Metformin.\n\nConclusion\nGLICLAGLAZE M 80 represents an effective treatment solution for managing Type 2 diabetes, combining two powerful antidiabetic agents to improve glycemic control and reduce the risk of diabetes complications. Patients should maintain regular consultations with their healthcare provider to tailor their treatment plan according to their specific needs, ensuring the best possible outcomes in diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-m-80-133420\n\n\n\n\n\n", "price": 137.0, "discountamount": 41.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "risk", "time", "Order", "meals", "EMAIL", "nausea", "500 mg", "Action", "patient", "disease", "diarrhea", "Benefits", "decrease", "Mechanism", "Metformin", "component", "inclusion", "Conclusion", "blood flow", "gliclazide", "individuals", "information", "body weight", "combination", "Introduction", "muscle cells", "tolerability", "sterispharma", "hypoglycemia", "sterisonline", "starting dose", "effectiveness", "CALL/WHATSAPP", "GLICLAGLAZE M", "treatment plan", "specific needs", "Type 2 diabetes", "oral medication", "robust approach", "drug absorption", "high blood sugar", "Dose adjustments", "glycemic control", "different aspects", "insulin secretion", "regular monitoring", "sulfonylurea class", "synergistic effect", "protective effects", "healthcare provider", "insulin sensitivity", "potential reduction", "diabetes management", "blood glucose levels", "regular consultations", "pancreatic beta cells", "Administration Dosage", "best possible outcomes", "blood sugar regulation", "Potential side effects", "specialized medication", "diabetes complications", "vascular complications", "gastrointestinal symptoms", "peripheral glucose uptake", "hepatic glucose production", "previous medication regimen", "effective treatment solution", "diabetes-related complications", "two powerful antidiabetic agents", "two effective antidiabetic agents", "potential gastrointestinal side effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1287, "imageuri": "https://productimages.withfloats.com/actual/665ef5c0ca75628a5853ff45.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef5c0ca75628a5853ff45.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:08:45.584Z", "updatedon": "2024-06-04T11:08:45.584Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gliclaglaze-m-80-/1287", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE M 80 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665ef17474d94b15a06c31e2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE M 40 ", "description": "GLICLAGLAZE M 40 \ngliclazide (40mg),Metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 40 is a combination medication designed to manage blood sugar levels in individuals with Type 2 diabetes. This oral treatment integrates two potent antidiabetic agents: Gliclazide (40 mg) and Metformin (500 mg), each playing a crucial role in diabetes control.\n\nHow It Works\n\nGliclazide (40 mg): As a sulfonylurea, Gliclazide works by stimulating the release of insulin from the pancreatic beta cells. Insulin is the hormone responsible for reducing blood glucose levels. Gliclazide also enhances the sensitivity of peripheral tissues to insulin and reduces the likelihood of clot formation, which is a common complication in diabetes patients.\nMetformin (500 mg): Metformin acts primarily by reducing glucose production in the liver. It also improves insulin sensitivity, enhancing peripheral glucose uptake and utilization. Unlike many other antidiabetic medications, Metformin does not cause hypoglycemia (low blood sugar) and is often associated with weight loss.\nBenefits\nThe dual mechanism of GLICLAGLAZE M 40 offers a comprehensive approach to diabetes management by not only improving insulin production and sensitivity but also addressing the hepatic release of glucose. This combination reduces blood sugar levels effectively while minimizing the risk of side effects common to other diabetes treatments, such as hypoglycemia.\n\nUsage Guidelines\n\nDosage: Typically, the initial dosage is guided by the patient’s current treatment regimen, effectiveness, and tolerability. Adjustment in dosage should be made based on the patient’s blood glucose response, under the supervision of a healthcare provider.\nAdministration: GLICLAGLAZE M 40 should be taken with meals to reduce gastrointestinal side effects and to enhance absorption.\nSide Effects\nWhile GLICLAGLAZE M 40 is generally well-tolerated, it may cause some side effects. Common ones include gastrointestinal disturbances such as nausea and diarrhea, which are often transient. Hypoglycemia may occur, but it is less frequent due to the mitigating action of Metformin.\n\nConclusion\nGLICLAGLAZE M 40 is a cornerstone in the pharmacological treatment of Type 2 diabetes, offering benefits derived from the combined effects of Gliclazide and Metformin. It is essential for patients to follow their healthcare provider’s instructions and to maintain regular check-ups to optimize treatment outcomes and prevent complications. This medication enables patients to manage their diabetes more effectively and improve their quality of life.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-m-40-133419\n\n\n\n\n\n\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "life", "risk", "liver", "meals", "40 mg", "Order", "EMAIL", "500 mg", "nausea", "quality", "hormone", "diarrhea", "Benefits", "Metformin", "gliclazide", "Adjustment", "likelihood", "Conclusion", "absorption", "utilization", "cornerstone", "information", "supervision", "individuals", "weight loss", "sulfonylurea", "hypoglycemia", "Introduction", "tolerability", "sterisonline", "instructions", "sterispharma", "crucial role", "complications", "GLICLAGLAZE M", "CALL/WHATSAPP", "effectiveness", "oral treatment", "dual mechanism", "clot formation", "Administration", "initial dosage", "Type 2 diabetes", "hepatic release", "low blood sugar", "diabetes control", "combined effects", "mitigating action", "diabetes patients", "regular check-ups", "blood sugar levels", "treatment outcomes", "peripheral tissues", "glucose production", "insulin production", "diabetes management", "insulin sensitivity", "common complication", "healthcare provider", "blood glucose levels", "pancreatic beta cells", "combination medication", "blood glucose response", "comprehensive approach", "Usage Guidelines Dosage", "pharmacological treatment", "peripheral glucose uptake", "current treatment regimen", "other diabetes treatments", "gastrointestinal disturbances", "gastrointestinal side effects", "two potent antidiabetic agents", "many other antidiabetic medications" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1284, "imageuri": "https://productimages.withfloats.com/actual/665ef175c06ee12d88caa810.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef175c06ee12d88caa810.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T10:50:28.577Z", "updatedon": "2024-06-04T10:50:28.577Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-m-40-/1284", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE M 40 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68c29ba02244c906e7790e2b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TELAVINCE 300", "description": "TELAVINCE 300 is a high-quality antiviral medication containing Tenofovir Disoproxil Fumarate 300 mg, specifically formulated for the effective management of HIV-1 infection and chronic Hepatitis B in adults and adolescents. Manufactured under strict pharmaceutical standards, TELAVINCE 300 offers consistent, potent, and clinically proven antiviral action, helping to suppress viral replication and improve immune function.\n\nTenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI). It works by interfering with the enzyme reverse transcriptase, which is essential for viral replication in HIV and Hepatitis B viruses. By inhibiting this enzyme, TELAVINCE 300 reduces the amount of virus in the body, helping to prevent further immune system damage and liver complications.\n\n \nKey Indications:\n \n\nTELAVINCE 300 is indicated for:\n\nHIV-1 Infection: In combination with other antiretroviral agents for the treatment of HIV-1 in adults and adolescents (aged 12 years and older, weighing at least 35 kg).\n\nChronic Hepatitis B: For the treatment of chronic hepatitis B virus infection in adults and adolescents with compensated liver disease and evidence of active viral replication.\n\n \nMechanism of Action:\n \nTenofovir Disoproxil Fumarate is a prodrug of tenofovir, which, once absorbed and metabolized in the body, is converted into tenofovir diphosphate, the active form. Tenofovir diphosphate acts as a competitive inhibitor of reverse transcriptase, incorporating itself into the viral DNA chain and causing premature chain termination. This process disrupts the life cycle of the virus, significantly reducing its ability to multiply and spread.\n\n \nDosage and Administration:\n \n\nRecommended Dose for Adults and Adolescents (≥12 years, ≥35 kg): One tablet (300 mg) once daily, preferably with food.\n\nFor HIV Treatment: Administer in combination with other antiretroviral medications as per the treatment regimen.\n\nFor Chronic Hepatitis B: Monotherapy or as part of combination therapy, depending on patient condition and physician's assessment.\n\nDosage adjustments may be required in patients with renal impairment. Close monitoring is recommended for patients with existing kidney disease.\n\n \nKey Benefits of TELAVINCE 300:\n \n\nPotent Antiviral Action: Rapid and sustained suppression of HIV and HBV replication.\nOnce-Daily Dosing: Improves patient compliance and treatment adherence.\n\nBacked by Clinical Research: Proven efficacy in managing viral load and improving immune markers (CD4 count).\n\nTrusted Quality: Manufactured under GMP-certified facilities with stringent quality control processes.\n\nPart of First-Line Therapy: Recommended in various national and international treatment guidelines for HIV and Hepatitis B.\n\n \nSafety and Precautions:\n \n\nRenal Monitoring: Tenofovir may affect kidney function. Routine renal function tests are recommended before and during treatment.\n\nBone Mineral Density: Long-term use may reduce bone mineral density. Consider monitoring in patients at risk of osteopenia or osteoporosis.\n\nHepatic Flare: Discontinuation of therapy in hepatitis B patients may result in severe acute exacerbations. Liver function should be closely monitored post-treatment.\n\nLactic Acidosis and Hepatomegaly: Rare but serious side effects. Patients presenting symptoms such as abdominal pain, fatigue, or difficulty breathing should seek immediate medical attention.\n\n \n\nPossible Side Effects:\n \n\nMost patients tolerate TELAVINCE 300 well. However, some may experience:\n\nNausea\n\nDiarrhea\n\nHeadache\n\nFatigue\n\nRash\n\nDizziness\n\nDecreased bone mineral density\n\nRenal impairment (in rare cases)\n\nIf any side effects persist or worsen, consult a healthcare professional immediately.\n\n \nStorage Instructions:\n \n\nStore in a cool, dry place below 30°C.\n\nProtect from light and moisture.\n\nKeep out of reach of children.\n\n \n\nWhy Choose TELAVINCE 300?\n \n\nTELAVINCE 300 offers a dependable, clinically validated solution for the long-term management of HIV and Hepatitis B. With its once-daily dosing and proven effectiveness, TELAVINCE 300 is an ideal choice for patients and healthcare providers looking for quality, safety, and therapeutic reliability. It is manufactured by a trusted name in healthcare, ensuring every tablet meets global pharmaceutical standards.\n\n \nDisclaimer:\n \n\nThis product description is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor or healthcare provider before starting any medication.", "price": 1480.0, "discountamount": 444.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2179, "imageuri": "https://productimages.withfloats.com/actual/68c29ba3794abb27ab248d73.png", "tileimageuri": "https://productimages.withfloats.com/tile/68c29ba3794abb27ab248d73.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-11T09:51:28.508Z", "updatedon": "2025-09-11T09:51:28.508Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/telavince-300/2179", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Tenofovir Disoproxil Fumarate Tablets ip 300 mg", "category": "GENERAL RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 550.0, "discountamount": 165.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-08-28T09:46:19.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 100 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6891f29bfb7044dfb2d43adf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "MAGRAL 160", "description": "MAGRAL 160 is a pharmaceutical medication containing megestrol acetate 160 mg, a synthetic progestin known for its potent antineoplastic and appetite-stimulating properties. This drug is primarily prescribed to manage significant health challenges such as unexplained weight loss, anorexia, and cachexia, especially in patients suffering from chronic conditions like cancer or AIDS. Additionally, megestrol acetate functions as a hormone therapy agent employed in the treatment of certain hormone-sensitive malignancies. Its dual action both supports tumor management and improves patients' nutritional status by stimulating appetite and promoting weight gain, thereby enhancing overall quality of life. The drug is regarded as a crucial option in oncology and palliative care for managing complex conditions related to hormone-dependent cancers and severe wasting syndromes.\n\nWhat is MAGRAL 160?\nMAGRAL 160 is an oral medication formulated with megestrol acetate 160 mg, a synthetic progestin hormone derivative. It works primarily by modulating hormone receptors and altering hormone levels that influence the growth of hormone-responsive tumors such as breast and endometrial cancers. Apart from its antineoplastic action, it stimulates appetite by acting on the hypothalamic centers responsible for hunger, helping patients suffering from severe weight loss regain a healthy appetite and weight.\n\nUses of MAGRAL 160\n\nTo treat hormone-dependent cancers, specifically advanced breast cancer and endometrial cancer.\n\nTo stimulate appetite and promote weight gain in patients experiencing anorexia, cachexia, or unexplained severe weight loss related to chronic illnesses like cancer or AIDS.\n\nTo manage wasting syndromes that lead to malnutrition and significant weight loss.\n\nTo serve as an antineoplastic agent in hormone-sensitive malignancies.\n\nIn short, MAGRAL 160 is primarily used to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.\n\nSide Effects of MAGRAL 160\n\nWeight gain (often desirable but can be excessive)\n\nFluid retention and edema (swelling)\n\nNausea and vomiting\n\nDiarrhea or constipation\n\nVaginal bleeding or spotting in women\n\nFatigue, weakness, and insomnia\n\nHeadache and dizziness\n\nIncreased risk of blood clots (deep vein thrombosis or pulmonary embolism)\n\nHormonal imbalances, such as decreased sex hormone levels, which can lead to sexual dysfunction or bone density loss\n\nAllergic reactions including rash or itching\n\nPatients should report severe or unusual symptoms, especially signs of blood clots such as limb swelling, chest pain, or sudden shortness of breath, immediately to their healthcare provider.\n\nPrecautions before Using MAGRAL 160\n\nInform your doctor if you are pregnant, breastfeeding, or planning to conceive as MAGRAL 160 is contraindicated in pregnancy.\n\nDisclose any history of blood clots, cardiovascular diseases, liver or kidney impairment.\n\nPatients with diabetes should monitor blood sugar closely as megestrol acetate may cause hyperglycemia.\n\nAvoid sudden discontinuation without medical advice to prevent potential hormonal withdrawal effects.\n\nRegular monitoring is required, including hormone levels and blood tests, to assess efficacy and safety during treatment.\n\nUse cautiously in patients at risk for deep vein thrombosis or pulmonary embolism due to increased clotting risks.\n\nDrug Interactions: What Drugs Interact with MAGRAL 160?\n\nCYP3A4 enzyme inducers (e.g., rifampin, phenytoin) may reduce the effectiveness of megestrol acetate by increasing its metabolism.\n\nConcurrent use with blood thinners (anticoagulants) requires careful monitoring as MAGRAL 160 might influence clotting parameters.\n\nCombining with drugs that affect hormonal pathways, such as other hormonal therapies or corticosteroids, may alter treatment outcomes.\n\nInteractions with diabetes medications might necessitate dose adjustment due to potential effects on blood sugar control.\n\nCareful medical supervision is necessary when used with immunosuppressants or other chemotherapy agents to avoid additive side effects or altered drug levels.\n\nConclusion\nMAGRAL 160, containing megestrol acetate 160 mg, is a clinically validated medication widely used to manage complex conditions such as hormone-dependent cancers as well as severe weight loss due to anorexia and cachexia. Its unique ability to act both as an antineoplastic agent and an appetite stimulant makes it invaluable in improving patient outcomes, nutritional status, and overall quality of life. Patients prescribed MAGRAL 160 should adhere strictly to their healthcare provider’s instructions and report any adverse effects promptly. This medication should always be used under medical supervision to ensure optimal benefits and minimize risks.", "price": 810.0, "discountamount": 243.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2156, "imageuri": "https://productimages.withfloats.com/actual/6891f2a0115b51057b971998.png", "tileimageuri": "https://productimages.withfloats.com/tile/6891f2a0115b51057b971998.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-05T12:01:31.195Z", "updatedon": "2025-08-05T12:01:31.195Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/magral-160/2156", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "megestrol acetate 160 mg", "category": "Gynaecology", "tags": [ "megestrol acetate 160 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }